At the recent American Diabetes Association (ADA) Scientific Sessions there were reportedly questions raised about whether there is an increased risk of Fournier’s gangrene when using Farxiga as well as other SGLT2 inhibitor diabetes drugs such as Invokana and Jardiance. From this July 18, 2019 article published online by Medscape, “Fournier … [Read more...]
Cases Of Fournier Gangrene Associated With Diabetes Drugs Invokana, Jardiance, And Farxiga
The FDA has identified 55 unique cases of Fournier gangrene associated with diabetes drugs in the Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors class between March 1, 2013 and January 31, 2019. Of those Fournier gangrene cases, 21 cases were associated with Invokana (canagliflozin), 18 cases were associated with Jardiance (empagliflozin), and … [Read more...]
Lower Limb Amputations From All SGLT2 Inhibitors, or Just Invokana?
A “Black-Box Warning” about the increased risk of lower limb amputations was added to the drug labels for Invokana and Invokamet in July 2017. Since that time there has been a mix of opinions expressed in the medical literature about whether or not lower limb amputations are a side effect of all diabetes medicines in the sodium-glucose … [Read more...]
Farxiga And Jardiance Have Two-Time Increased Risk For Amputations
Patients using the diabetes drugs Farxiga and Jardiance had twice the risk for lower limb amputations relative to certain other diabetes medicines, according to a new observational study published in November 2018 by The BMJ medical journal in. However, in the US only a third diabetes drugs in the sodium-glucose cotransporter 2 (SGLT2) … [Read more...]
Amputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
There seems to be an increasing degree of acknowledgement in the medical literature that these lower limb amputations are drug-class side effects of SGLT2 inhibitors class diabetes medicines such as Jardiance and Farxiga in addition to Invokana. For example, from this recent Medscape news report, “Canagliflozin (Invokana) Gets FDA Nod for CV … [Read more...]
Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects
New medical evidence indicates that lower limbs amputations may be a “drug-class” side effect for all of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor diabetes drugs which have been approved by the FDA to date. We get the following explanation of this increased risk of toe, foot, or leg amputations for Jardiance and Farxiga as well as … [Read more...]
Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
From this August 29, 2018 Drug Safety Communication, “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes”, we get the following details about this new safety issue for Invokana, Farxiga, Jardiance, and similar diabetes drugs: Fournier’s gangrene is an extremely rare but life-threatening … [Read more...]
Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
During late August a presentation at the 2018 European Society of Cardiology Congress in Munich, Germany included evidence that the SGLT-2 inhibitors Invokana, Jardiance, and Farxiga all are associated with twofold increases for lower-limb amputations when compared to GLP-1 receptor agonists diabetes drugs. An August 25, 2018 Healio.com article, … [Read more...]
Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older diabetes drugs such as sulfonylureas, metformin, and thiazolidinediones. This finding was reported in the article “Association Between … [Read more...]
New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January
Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet. These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]